BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 38298549)

  • 1. Metastases-directed local therapies (MDT) beyond genuine oligometastatic disease (OMD): Indications, endpoints and the role of imaging.
    Widder J; Simek IM; Goldner GM; Heilemann G; Ubbels JF
    Clin Transl Radiat Oncol; 2024 Mar; 45():100729. PubMed ID: 38298549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
    Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
    Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oligometastatic breast cancer: where are we now and where are we headed?-a narrative review.
    Kent CL; McDuff SGR; Salama JK
    Ann Palliat Med; 2021 May; 10(5):5954-5968. PubMed ID: 32921069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A predictive model of polymetastatic disease from a multicenter large retrospectIve database on colorectal lung metastases treated with stereotactic ablative radiotherapy: The RED LaIT-SABR study.
    Nicosia L; Franceschini D; Perrone-Congedi F; Molinari A; Gerardi MA; Rigo M; Mazzola R; Perna M; Scotti V; Fodor A; Iurato A; Pasqualetti F; Gadducci G; Chiesa S; Niespolo RM; Bruni A; Cappelli A; D'Angelo E; Borghetti P; Di Marzo A; Ravasio A; De Bari B; Sepulcri M; Aiello D; Mortellaro G; Sangalli C; Franceschini M; Montesi G; Aquilanti FM; Lunardi G; Valdagni R; Fazio I; Scarzello G; Vavassori V; Maranzano E; Maria Magrini S; Arcangeli S; Gambacorta MA; Valentini V; Paiar F; Ramella S; Di Muzio NG; Loi M; Jereczek-Fossa BA; Casamassima F; Osti MF; Scorsetti M; Alongi F
    Clin Transl Radiat Oncol; 2023 Mar; 39():100568. PubMed ID: 36935855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review.
    Le Guevelou J; Sargos P; Siva S; Ploussard G; Ost P; Gillessen S; Zilli T
    Eur Urol Focus; 2023 Jan; 9(1):114-124. PubMed ID: 36151031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy.
    Nicosia L; Cuccia F; Mazzola R; Ricchetti F; Figlia V; Giaj-Levra N; Rigo M; Tomasini D; Pasinetti N; Corradini S; Ruggieri R; Alongi F
    Strahlenther Onkol; 2020 Sep; 196(9):813-820. PubMed ID: 32399637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oligometastatic Disease (OMD): The Classification and Practical Review of Prospective Trials.
    Izmailov T; Ryzhkin S; Borshchev G; Boichuk S
    Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Metastasis-Directed Therapy in Genitourinary Cancers.
    Lee KN; Huynh MA
    Curr Treat Options Oncol; 2024 May; 25(5):605-616. PubMed ID: 38573430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic ablative radiation therapy in metastatic prostate cancer.
    Bazyar S; Mannuel H; Tran PT
    Curr Opin Oncol; 2024 May; 36(3):180-185. PubMed ID: 38362949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Oligometastasis with Stereotactic Ablative Radiation Therapy or Surgery in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review of Prospective Clinical Trials.
    Connor MJ; Smith A; Miah S; Shah TT; Winkler M; Khoo V; Ahmed HU
    Eur Urol Oncol; 2020 Oct; 3(5):582-593. PubMed ID: 32891600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of Prospective Trials Assessing the Role of Stereotactic Body Radiation Therapy for Metastasis-directed Treatment in Oligometastatic Genitourinary Cancers.
    Huynh MA; Tang C; Siva S; Berlin A; Hannan R; Warner A; Koontz B; De Meeleer G; Palma D; Ost P; Tran PT
    Eur Urol Oncol; 2023 Feb; 6(1):28-38. PubMed ID: 36283936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary oligometastases: metastasectomy or stereotactic ablative radiotherapy?
    Widder J; Klinkenberg TJ; Ubbels JF; Wiegman EM; Groen HJ; Langendijk JA
    Radiother Oncol; 2013 Jun; 107(3):409-13. PubMed ID: 23773410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).
    Hasan H; Deek MP; Phillips R; Hobbs RF; Malek R; Radwan N; Kiess AP; Dipasquale S; Huang J; Caldwell T; Leitzel J; Wendler D; Wang H; Thompson E; Powell J; Dudley S; Deville C; Greco SC; Song DY; DeWeese TL; Gorin MA; Rowe SP; Denmeade S; Markowski M; Antonarakis ES; Carducci MA; Eisenberger MA; Pomper MG; Pienta KJ; Paller CJ; Tran PT
    BMC Cancer; 2020 Jun; 20(1):492. PubMed ID: 32487038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic disease in the context of new consensus definitions.
    Li GJ; Arifin AJ; Al-Shafa F; Cheung P; Rodrigues GB; Palma DA; Louie AV
    Ann Palliat Med; 2021 May; 10(5):6045-6051. PubMed ID: 32787370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer.
    Rogowski P; Trapp C; von Bestenbostel R; Schmidt-Hegemann NS; Shi R; Ilhan H; Kretschmer A; Stief C; Ganswindt U; Belka C; Li M
    Radiat Oncol; 2021 Jun; 16(1):125. PubMed ID: 34193194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time.
    Dhondt B; De Bleser E; Claeys T; Buelens S; Lumen N; Vandesompele J; Beckers A; Fonteyne V; Van der Eecken K; De Bruycker A; Paul J; Gramme P; Ost P
    World J Urol; 2019 Dec; 37(12):2557-2564. PubMed ID: 30578441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active involvement of patients, radiation oncologists, and surgeons in a multidisciplinary team approach: Guiding local therapy in recurrent, metastatic rectal cancer.
    Choi SH; Yang G; Koom WS; Yang SY; Kim SS; Lim JS; Kim HS; Shin SJ; Chang JS
    Cancer Med; 2023 Nov; 12(22):21057-21067. PubMed ID: 37909227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastasis-directed Therapy in Prostate Cancer: Prognostic Significance of the ESTRO/EORTC Classification in Oligometastatic Bone Disease.
    Nicholls L; Chapman E; Khoo V; Suh YE; Tunariu N; Wang Y; van As N
    Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):63-69. PubMed ID: 34756755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic radiotherapy in the management of oligometastatic and recurrent head and neck cancer: a single-center experience.
    Mohamed AA; Goncalves M; Singh BP; Tometten M; Rashad A; Hölzle F; Hackenberg S; Eble M
    Strahlenther Onkol; 2024 May; 200(5):400-408. PubMed ID: 38063900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review.
    Farolfi A; Hadaschik B; Hamdy FC; Herrmann K; Hofman MS; Murphy DG; Ost P; Padhani AR; Fanti S
    Eur Urol Oncol; 2021 Oct; 4(5):714-730. PubMed ID: 33750684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.